# Safety Study of CC312 in Autoimmune Disease Patients

> **NCT06888960** · EARLY_PHASE1 · RECRUITING · sponsor: **CytoCares Inc** · enrollment: 18 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Idiopathic Inflammatory Myopathy (IIM)
- Systemic Sclerosis (SSc)
- Rheumatoid Arthritis (RA)
- Primary Immune Thrombocytopenia (ITP)
- Autoimmune Hemolytic Anemia

## Interventions

- **BIOLOGICAL:** CC312

## Key facts

- **NCT ID:** NCT06888960
- **Lead sponsor:** CytoCares Inc
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2026-11-08
- **Final completion:** 2026-11-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888960, "Safety Study of CC312 in Autoimmune Disease Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06888960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*